Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00669019|
Recruitment Status : Completed
First Posted : April 29, 2008
Results First Posted : January 27, 2014
Last Update Posted : May 21, 2014
|Condition or disease||Intervention/treatment||Phase|
|Recurrent Melanoma Stage IIA Melanoma Stage IIB Melanoma Stage IIC Melanoma Stage IV Melanoma||Drug: saracatinib||Phase 2|
I. To determine whether the Src kinase inhibitor, AZD0530 (saracatinib), has single agent clinical activity in patients with advanced melanoma.
II. To determine whether this drug will increase progression-free survival of these patients from 3 months to 4.5 months.
I. To determine whether this drug may inhibit the activation of peripheral blood T cells analyzed ex vivo.
Patients receive saracatinib orally (PO) once daily (QD) in the absence of disease progression or unacceptable toxicity.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||23 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 2 Study of AZD0530 in Metastatic Melanoma|
|Study Start Date :||July 2006|
|Primary Completion Date :||January 2011|
|Study Completion Date :||January 2011|
Patients receive saracatinib 175 mg oral once daily in the absence of disease progression or unacceptable toxicity.
Other Name: AZD0530
- Objective Response Rate [ Time Frame: Up to 25 weeks ]
Response will be evaluated in this study using the Response Evaluation Criteria in Solid Tumors (RECIST). A sum of the longest diameter (LD) for all target lesions will be calculated and reported as the baseline sum LD. The baseline sum LD will be used as reference by which to characterize the objective tumor response. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum LD; Objective response = CR + PR.
CT scans will be performed at baseline and every 4-8 weeks while on study.
- Progression-free Survival [ Time Frame: Up to 2 years ]Progression will be evaluated in this study using the RECIST criteria (the appearance of new lesions and/or at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study). Progression-free survival time was calculated as the time from treatment start to date of progression or death, whichever comes first.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00669019
|United States, Illinois|
|University of Chicago Comprehensive Cancer Center|
|Chicago, Illinois, United States, 60637-1470|
|Principal Investigator:||Thomas Gajewski||University of Chicago Comprehensive Cancer Center|